{"id":"ilaprazole","rwe":[{"pmid":"41852672","year":"2026","title":"Efficacy and safety of ilaprazole for stress ulcer - associated upper gastrointestinal bleeding prophylaxis in critically ill patients: a randomized, double-blind, non-inferiority phase 3 trial.","finding":"","journal":"Annals of intensive care","studyType":"Clinical Study"},{"pmid":"41592966","year":"2026","title":"Assessment of diverse proton pump inhibitor combined with bismuth quadruple regimens and risk factors for Helicobacter pylori eradication in China: A retrospective single-center study.","finding":"","journal":"Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology","studyType":"Clinical Study"},{"pmid":"41311097","year":"2026","title":"Pharmacokinetics and Bioequivalence of Ilaprazole Enteric-Coated Tablets in Healthy Chinese Volunteers: A Two-Sequence, Four-Period, Fully Replicated Crossover Study.","finding":"","journal":"Clinical pharmacology in drug development","studyType":"Clinical Study"},{"pmid":"41211681","year":"2025","title":"Different Doses of Ilaprazole for Dual Therapy Versus Bismuth-Quadruple Therapy for Helicobacter pylori Infection: A Three-Arm, Randomized Clinical Trial.","finding":"","journal":"Helicobacter","studyType":"Clinical Study"},{"pmid":"40990560","year":"2025","title":"In vitro anti-Helicobacter pylori activity of ilaprazole used alone and in combination with other components of quadruple therapy.","finding":"","journal":"Microbiology spectrum","studyType":"Clinical Study"}],"tags":[{"label":"Proton Pump Inhibitors","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Potassium-transporting ATPase","category":"target"},{"label":"ATP4A","category":"gene"},{"label":"ATP4B","category":"gene"},{"label":"Active","category":"status"},{"label":"Gastroesophageal reflux disease","category":"indication"},{"label":"Peptic ulcer","category":"indication"}],"phase":"marketed","safety":{"safetySignals":[{"llr":86.924,"date":"","count":9,"signal":"Occupational dermatitis","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=87)"},{"llr":76.247,"date":"","count":8,"signal":"Occupational exposure to air contaminants","source":"DrugCentral FAERS","actionTaken":"Reported 8 times (LLR=76)"}],"drugInteractions":[{"url":"/drug/clopidogrel","drug":"clopidogrel","action":"Avoid combination","effect":"esomeprazole may diminish the antiplatelet effect of clopidogrel","source":"DrugCentral","drugSlug":"clopidogrel"},{"url":"/drug/dasatinib","drug":"dasatinib","action":"Avoid combination","effect":"Proton Pump Inhibitors may decrease the serum concentration of Dasatinib","source":"DrugCentral","drugSlug":"dasatinib"},{"url":"/drug/delavirdine","drug":"delavirdine","action":"Avoid combination","effect":"Proton Pump Inhibitors may decrease the serum concentration of Delavirdine","source":"DrugCentral","drugSlug":"delavirdine"},{"url":"/drug/erlotinib","drug":"erlotinib","action":"Avoid combination","effect":"Proton Pump Inhibitors may decrease the serum concentration of Erlotinib","source":"DrugCentral","drugSlug":"erlotinib"},{"url":"/drug/nelfinavir","drug":"nelfinavir","action":"Avoid combination","effect":"Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Nelfinavir","source":"DrugCentral","drugSlug":"nelfinavir"},{"url":"/drug/ponatinib","drug":"ponatinib","action":"Avoid combination","effect":"Proton Pump Inhibitors may decrease the serum concentration of Ponatinib","source":"DrugCentral","drugSlug":"ponatinib"},{"url":"/drug/rilpivirine","drug":"rilpivirine","action":"Avoid combination","effect":"Proton Pump Inhibitors may decrease the serum concentration of Rilpivirine","source":"DrugCentral","drugSlug":"rilpivirine"},{"url":"/drug/risedronic-acid","drug":"risedronic acid","action":"Avoid combination","effect":"Proton Pump Inhibitors may diminish the therapeutic effect of Risedronate","source":"DrugCentral","drugSlug":"risedronic-acid"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ILAPRAZOLE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:37:14.413165+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Ilaprazole","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T01:37:23.896840+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:37:22.639181+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ILAPRAZOLE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:37:22.860226+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Potassium-transporting ATPase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:37:23.896763+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2106370/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:37:23.557707+00:00"}},"allNames":"noltec","offLabel":[],"synonyms":["IY-81149","IY81149","IY 81149","ilaprazole","noltec"],"timeline":[{"date":"2008-10-28","type":"positive","source":"DrugCentral","milestone":"Korean Food and Drug Administration (KFDA) approval"}],"approvals":[{"date":"2008-10-28","orphan":false,"company":"","regulator":"Korean Food and Drug Administration (KFDA)"}],"brandName":"Noltec","ecosystem":[{"indication":"Gastroesophageal reflux disease","otherDrugs":[{"name":"algeldrate","slug":"algeldrate","company":"Sanofi Aventis Us"},{"name":"almasilate","slug":"almasilate","company":""},{"name":"cimetidine","slug":"cimetidine","company":""},{"name":"cisapride","slug":"cisapride","company":""}],"globalPrevalence":null},{"indication":"Peptic ulcer","otherDrugs":[{"name":"algeldrate","slug":"algeldrate","company":"Sanofi Aventis Us"},{"name":"almasilate","slug":"almasilate","company":""},{"name":"chlordiazepoxide","slug":"chlordiazepoxide","company":"Valeant Pharm Intl"},{"name":"dexlansoprazole","slug":"dexlansoprazole","company":"Takeda Pharms Usa"}],"globalPrevalence":64000000}],"mechanism":{"target":"Potassium-transporting ATPase","targets":[{"gene":"ATP4A","source":"DrugCentral","target":"Potassium-transporting ATPase","protein":"Potassium-transporting ATPase alpha chain 1"},{"gene":"ATP4B","source":"DrugCentral","target":"Potassium-transporting ATPase","protein":"Potassium-transporting ATPase subunit beta"}],"modality":"Small Molecule","drugClass":"Proton Pump Inhibitors","explanation":"","oneSentence":"","technicalDetail":"Ilaprazole selectively and irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby reducing gastric acid secretion."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Ilaprazole","title":"Ilaprazole","extract":"Ilaprazole is a proton pump inhibitor (PPI) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and duodenal ulcer."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3961","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ILAPRAZOLE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ILAPRAZOLE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Ilaprazole","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T12:00:41.990875","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:37:25.227703+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"dexlansoprazole","drugSlug":"dexlansoprazole","fdaApproval":"2009-01-30","patentExpiry":"Sep 27, 2026","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"esomeprazole","drugSlug":"esomeprazole","fdaApproval":"2001-02-20","patentExpiry":"Dec 8, 2036","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"lansoprazole","drugSlug":"lansoprazole","fdaApproval":"1995-05-10","patentExpiry":"Apr 21, 2036","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"omeprazole","drugSlug":"omeprazole","fdaApproval":"1989-09-14","patentExpiry":"Dec 8, 2036","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"pantoprazole","drugSlug":"pantoprazole","fdaApproval":"2000-02-02","patentExpiry":"Jun 7, 2026","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"rabeprazole","drugSlug":"rabeprazole","fdaApproval":"1999-08-19","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"genericName":"ilaprazole","indications":{"approved":[{"name":"Gastroesophageal reflux disease","source":"DrugCentral","snomedId":235595009,"regulator":"FDA"},{"name":"Peptic ulcer","source":"DrugCentral","snomedId":13200003,"regulator":"FDA","usPrevalence":null,"globalPrevalence":64000000,"prevalenceMethod":"curated","prevalenceSource":"Aliment Pharmacol Ther, 2009 (PMID:19220208)"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"dexlansoprazole","brandName":"dexlansoprazole","genericName":"dexlansoprazole","approvalYear":"2009","relationship":"same-target"},{"drugId":"esomeprazole","brandName":"esomeprazole","genericName":"esomeprazole","approvalYear":"2001","relationship":"same-target"},{"drugId":"lansoprazole","brandName":"lansoprazole","genericName":"lansoprazole","approvalYear":"1995","relationship":"same-target"},{"drugId":"omeprazole","brandName":"omeprazole","genericName":"omeprazole","approvalYear":"1989","relationship":"same-target"},{"drugId":"pantoprazole","brandName":"pantoprazole","genericName":"pantoprazole","approvalYear":"2000","relationship":"same-target"},{"drugId":"rabeprazole","brandName":"rabeprazole","genericName":"rabeprazole","approvalYear":"1999","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT06284876","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer","status":"RECRUITING","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2024-07-23","conditions":["Peptic Ulcer"],"enrollment":416,"completionDate":"2027-02-28"},{"nctId":"NCT06725992","phase":"PHASE1","title":"Study to Evaluate Pharmacokinetic and Pharmacodynamic Drug Interactions and Safety of IY-NS250 and IY-NT-SR","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2024-01-30","conditions":["Pharmacokinetics","Pharmacodynamics"],"enrollment":56,"completionDate":"2024-08-14"},{"nctId":"NCT05509543","phase":"PHASE1","title":"Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2022-08-24","conditions":["Pharmacokinetics"],"enrollment":60,"completionDate":"2023-12-18"},{"nctId":"NCT05624229","phase":"PHASE4","title":"Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2023-10-01","conditions":["Upper Gastrointestinal Hemorrhage"],"enrollment":672,"completionDate":"2028-12-31"},{"nctId":"NCT05558150","phase":"PHASE1","title":"Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Ilaprazole and Aceclofenac","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2022-11-10","conditions":["Drug Interaction Potentiation"],"enrollment":24,"completionDate":"2022-12-22"},{"nctId":"NCT05237297","phase":"PHASE1","title":"Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Naproxen, Aceclofenac, Celecoxib and Ilaprazole","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2022-02-17","conditions":["Drug Interaction Potentiation"],"enrollment":72,"completionDate":"2022-07-27"},{"nctId":"NCT05841394","phase":"PHASE3","title":"A Multi-center, Double-blinding, Parallel and Positive-controlled Phase III Clinical Trial for Efficacy and Safety Evaluation of Ilaprazole Sodium for Injection on Prevention of Stress Ulcer Bleeding","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2021-07-16","conditions":["Stress Ulcer Bleeding"],"enrollment":449,"completionDate":"2022-04-28"},{"nctId":"NCT05617651","phase":"PHASE1","title":"Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T","status":"UNKNOWN","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2024-11-30","conditions":["Pharmacokinetics"],"enrollment":50,"completionDate":"2025-12-30"},{"nctId":"NCT05410223","phase":"NA","title":"Efficacy and Safety Study of Egg Yolk Antibody in Adjuvant Treatment of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2021-04-06","conditions":["Helicobacter Pylori Infection"],"enrollment":100,"completionDate":"2022-12-01"},{"nctId":"NCT05455372","phase":"NA","title":"Influence of Oral Hp Infection and Oral Related Factors on Gastric Hp Infection and Eradication Therapy","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Xi'an Jiaotong University","startDate":"2022-07-08","conditions":["Helicobacter Pylori Infection"],"enrollment":600,"completionDate":"2024-03-31"},{"nctId":"NCT05191875","phase":"NA","title":"Saccharomyces Boulardii as Pretreatment Before Rescue Therapy of Helicobacter Pylori","status":"COMPLETED","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2021-12-01","conditions":["Helicobacter Pylori Infection"],"enrollment":106,"completionDate":"2022-04-23"},{"nctId":"NCT03342456","phase":"PHASE4","title":"The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers","status":"COMPLETED","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2017-12-13","conditions":["Duodenal Ulcer Due to Helicobacter Pylori"],"enrollment":184,"completionDate":"2019-09-20"},{"nctId":"NCT03444883","phase":"PHASE3","title":"Phase III Study to Evaluate Safety and Efficacy of Ilaprazole in Patients With NERD","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2018-10-31","conditions":["Non-erosive Reflux Disease"],"enrollment":277,"completionDate":"2020-02-25"},{"nctId":"NCT02638584","phase":"PHASE4","title":"Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2015-12","conditions":["Gastric Cancer"],"enrollment":176,"completionDate":"2018-03"},{"nctId":"NCT02666976","phase":"PHASE4","title":"The Prospective Study on the Effect of Ilaprazole in Non-erosive Reflux Disease Patients; Focused on Histologic Findings and Inflammatory Biomarker","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2014-07","conditions":["Gastrointestinal Subepithelial Tumors"],"enrollment":20,"completionDate":"2016-01"},{"nctId":"NCT02648659","phase":"PHASE4","title":"The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in H.Pylori Patients","status":"COMPLETED","sponsor":"Kyungpook National University Hospital","startDate":"2016-03-02","conditions":["Peptic Ulcer"],"enrollment":50,"completionDate":"2017-02-14"},{"nctId":"NCT03362281","phase":"PHASE3","title":"Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2014-10","conditions":["Peptic Ulcer Hemorrhage"],"enrollment":540,"completionDate":"2015-04"},{"nctId":"NCT03362268","phase":"PHASE2","title":"IIaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2014-02","conditions":["Peptic Ulcer Hemorrhage"],"enrollment":180,"completionDate":"2014-07"},{"nctId":"NCT03139253","phase":"PHASE4","title":"Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment","status":"UNKNOWN","sponsor":"Yanqing Li","startDate":"2017-05-30","conditions":["Antimicrobial Susceptibility Testing","Triple Therapy"],"enrollment":120,"completionDate":"2017-06-30"},{"nctId":"NCT02988089","phase":"PHASE4","title":"Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2017-04-20","conditions":["Helicobacter Pylori Infection","Antimicrobial Susceptibility Testing"],"enrollment":480,"completionDate":"2017-09"},{"nctId":"NCT03099876","phase":"","title":"A Study on Eradication Rate of Triple Therapy According to Treatment Period and CYP2C19 Polymorphisms in H.Pylori Patients","status":"UNKNOWN","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2017-03-01","conditions":["Helicobacter Pylori Infection"],"enrollment":320,"completionDate":"2018-12-01"},{"nctId":"NCT02998437","phase":"PHASE1","title":"Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Clarithromycin, Amoxicillin and Ilaprazole","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2016-12","conditions":["Drug Interaction Potentiation"],"enrollment":28,"completionDate":"2017-01"},{"nctId":"NCT02873065","phase":"PHASE4","title":"Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2014-09","conditions":["Helicobacter Pylori Eradication"],"enrollment":0,"completionDate":"2015-06"},{"nctId":"NCT02860624","phase":"PHASE3","title":"Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2011-12","conditions":["Gastroesophageal Reflux Disease"],"enrollment":550,"completionDate":""},{"nctId":"NCT02847455","phase":"PHASE2,PHASE3","title":"Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2008-08","conditions":["Duodenal Ulcer"],"enrollment":408,"completionDate":""},{"nctId":"NCT02835560","phase":"PHASE4","title":"Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2013-06","conditions":["Helicobacter Pylori Eradication Antibiotic"],"enrollment":100,"completionDate":""},{"nctId":"NCT02401477","phase":"PHASE4","title":"Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2014-12","conditions":["Helicobacter Infections"],"enrollment":90,"completionDate":"2015-06"},{"nctId":"NCT02352701","phase":"","title":"Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.Pylori","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2012-12","conditions":["Helicobacter Infections"],"enrollment":320,"completionDate":"2014-03"},{"nctId":"NCT02084420","phase":"PHASE3","title":"Efficacy/Safety Study as H. Pylori Eradication of Triple Therapy for 7 Days Treatment","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2012-12","conditions":["Peptic Ulcer"],"enrollment":323,"completionDate":"2014-01"},{"nctId":"NCT01820143","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2005-02","conditions":["Healthy","Pharmacokinetics","Pharmacodynamics","Ilaprazole"],"enrollment":40,"completionDate":"2005-04"},{"nctId":"NCT01688544","phase":"PHASE1","title":"Pharmacokinetic/Pharmacodynamic Study of Ilaprazole to Evaluate the Effect of CYP Genetic Polymorphism","status":"COMPLETED","sponsor":"Inje University","startDate":"2009-01","conditions":["Healthy"],"enrollment":27,"completionDate":"2011-12"},{"nctId":"NCT00471094","phase":"PHASE2","title":"Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-05","conditions":["Esophagitis"],"enrollment":831,"completionDate":"2007-10"},{"nctId":"NCT01509261","phase":"PHASE3","title":"Efficacy Study of Ilaprazole to Treat Erosive Esophgitis","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2010-07","conditions":["Erosive Esophagitis","GERD"],"enrollment":292,"completionDate":"2011-06"},{"nctId":"NCT01107938","phase":"PHASE2","title":"Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients","status":"UNKNOWN","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2010-05","conditions":["Gastroesophageal Reflux Disease"],"enrollment":330,"completionDate":""},{"nctId":"NCT00953381","phase":"PHASE2","title":"Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 2)","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2004-10","conditions":["Duodenal Ulcer"],"enrollment":235,"completionDate":"2005-05"},{"nctId":"NCT00952978","phase":"PHASE3","title":"Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 3)","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2005-09","conditions":["Duodenal Ulcer"],"enrollment":496,"completionDate":"2006-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"776Q6XX45J","CHEBI":"CHEBI:135544","INN_ID":"8158","UMLSCUI":"C1881129","chemblId":"CHEMBL2106370","ChEMBL_ID":"CHEMBL2106370","DRUGBANK_ID":"DB11964","PUBCHEM_CID":"214351","IUPHAR_LIGAND_ID":"10512","MESH_SUPPLEMENTAL_RECORD_UI":"C119615"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"3.59 hours","clearance":"0.73 mL/min/kg","volumeOfDistribution":"0.19 L/kg"},"publicationCount":108,"therapeuticAreas":["Gastroenterology"],"biosimilarFilings":[],"recentPublications":[{"date":"2026","pmid":"41852672","title":"Efficacy and safety of ilaprazole for stress ulcer - associated upper gastrointestinal bleeding prophylaxis in critically ill patients: a randomized, double-blind, non-inferiority phase 3 trial.","journal":"Annals of intensive care"},{"date":"2026 Feb","pmid":"41592966","title":"Assessment of diverse proton pump inhibitor combined with bismuth quadruple regimens and risk factors for Helicobacter pylori eradication in China: A retrospective single-center study.","journal":"Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology"},{"date":"2026 Mar","pmid":"41311097","title":"Pharmacokinetics and Bioequivalence of Ilaprazole Enteric-Coated Tablets in Healthy Chinese Volunteers: A Two-Sequence, Four-Period, Fully Replicated Crossover Study.","journal":"Clinical pharmacology in drug development"},{"date":"2025 Nov-Dec","pmid":"41211681","title":"Different Doses of Ilaprazole for Dual Therapy Versus Bismuth-Quadruple Therapy for Helicobacter pylori Infection: A Three-Arm, Randomized Clinical Trial.","journal":"Helicobacter"},{"date":"2025 Nov 4","pmid":"40990560","title":"In vitro anti-Helicobacter pylori activity of ilaprazole used alone and in combination with other components of quadruple therapy.","journal":"Microbiology spectrum"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"Korean Food and Drug Administration (KFDA)","status":"approved","approval_date":"2008-10-28T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:37:25.227703+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}